ACE and hypertensive disorder: The subgroups of patients with newly diagnosed hypertension, aged 50–69 years, and without diabetes were found to be statistically more likely to achieve target BP when treated with AZL-M rather than an ACE-inhibitor; and the results were significant (Fig. 2).